Clinical Trials

Treatment with lenvatinib is associated with significant clinical improvement in patients with radioiodine-refractory differentiated thyroid cancer

A large, multi-center phase 3 study (SELECT trial) has found that patients with progressive, iodine refractory differentiated thyroid cancer have markedly improved progression free survival (PFS) when treated with lenvatinib, an oral tyrosine kinase inhibitor. Multiple ITOG members participated in the study, including lead author, Dr. Martin Schlumberger and senior author, Dr. Steven I. Sherman, current Chairman of ITOG.  The study, funded by the Eisai, the manufacturer of lenvatinib, was published in the New England Journal of Medicine, on February 12, 2015.On February 13th the FDA approved... Continue reading

ITOG Opens First Clinical Trial

ITOG is poised to open it’s first clinical trial for treatment of differentiated thyroid cancer. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, will examine whether patients who had progression of their thyroid cancer on a VEGR inhibitor benefit from treatment with Cabozantinib.NCI9312/OSU12154/RU241210I is an investigator-initiated, multicenter, open label, phase II trial of Cabozantinib in patients with radioiodine-refractory, differentiated thyroid cancer (DTC), who progressed on first-line therapy with a VEGFR antagonist. ITOG’s first... Continue reading

Contact

International Thyroid Oncology Group
5166 Commercial Drive
Yorkville, New York 13495